

would be the same as those considered by the SPRS.

The Subcommittee's responsibility is to develop funding recommendations for the NCIPC Director based on the results of the primary review, the relevance and balance of proposed research relative to the NCIPC programs and priorities, and to assure that unwarranted duplication of federally funded research does not occur. The secondary review Subcommittee has the latitude to recommend to the NCIPC Director, to reach over better-ranked proposals in order to assure maximal impact and balance of proposed research. The factors to be considered will include:

- a. The results of the primary review including the application's priority score as the primary factor in the selection process.
- b. The relevance and balance of proposed research relative to the NCIPC programs and priorities.
- c. The significance of the proposed activities in relation to the priorities and objectives stated in "Healthy People 2010," the Institute of Medicine report, "Reducing the Burden of Injury," and the NCIPC "Injury Research Agenda."
- d. Budgetary considerations including the extent to which the budget is reasonable, clearly justified, and consistent with the intended use of funds.

#### I. Other Requirements

##### Technical Reporting Requirements

Provide CDC with original plus two copies of:

1. Interim progress reports, no less than 90 days before the end of the budget period. The progress report will serve as your non-competing continuation application, and must contain the following elements:
  - a. Current Budget Period Activities Objectives.
  - b. Current Budget Period Financial Progress.
  - c. New Budget Period Program Proposed Activity Objectives.
  - d. Detailed Line-Item Budget and Justification.
  - e. Additional Requested Information.
2. Financial status reports, no more than 90 days after the end of the budget period.
3. Final financial and performance reports, no more than 90 days after the end of the project period.

Send all reports to the Grants Management Specialist identified in the "Where to Obtain Additional Information" section of this announcement.

#### Additional Requirements

The following additional requirements are applicable to this program. For a complete description of each, see Attachment I of the program announcement, as posted on the CDC Web site.

- AR-1 Human Subjects Requirements
  - AR-2 Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research
  - AR-9 Paperwork Reduction Act Requirements
  - AR-10 Smoke-Free Workplace Requirements
  - AR-11 Healthy People 2010
  - AR-12 Lobbying Restrictions
  - AR-13 Prohibition on Use of CDC funds for Certain Gun Control Activities
  - AR-14 Accounting System Requirements
  - AR-15 Proof of Non-Profit Status
  - AR-21 Small, Minority, and Women-Owned Business
  - AR-22 Research Integrity
- Executive order 12372 does not apply to this program.

#### J. Where To Obtain Additional Information

This and other CDC announcements, the necessary applications, and associated forms can be found on the CDC web site, Internet address: <http://www.cdc.gov>. Click on "Funding" then "Grants and Cooperative Agreements".

For general questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341-4146, Telephone: 770-488-2700.

For business management and budget assistance, contact: Wanda Allison, Grants Management Specialist, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341-4146, Telephone: 770-488-2645, E-mail address: [wallison@cdc.gov](mailto:wallison@cdc.gov).

For business management and budget assistance in the territories, contact: Angelia Hill, Grants Management Specialist, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341-4146, Telephone: (770) 488-2785, E-mail address: [aph8@cdc.gov](mailto:aph8@cdc.gov).

For program technical assistance, contact: Stacy Harper, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, MS F-41, Atlanta, GA 30341-3724, Telephone number (770) 488-4031, E-mail address: [slharper@cdc.gov](mailto:slharper@cdc.gov).

Dated: May 23, 2003.

**Sandra R. Manning,**

*Director, Procurement and Grants Office,  
Centers for Disease Control and Prevention.*  
[FR Doc. 03-13652 Filed 5-30-03; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Program Announcement 03057]

#### Cooperative Agreement for a National Poison Prevention and Control Program; Notice of Availability of Funds; Amendment

A notice announcing the availability of fiscal year (FY) 2003 funds for a cooperative agreement program for a national poison prevention and control program was published in the **Federal Register** on May 7, 2003, Volume 68, Number 88, on pages 24483-24485. The notice is amended as follows: On page 24483, in the second column, section E. Program Requirements, item 1(a) should read: Develop a plan to improve the current national toxicosurveillance system, with a focus on improvement of data collection and coding. Enhance real time data collection and aberration detection capabilities of TESS.

Dated: May 23, 2003.

**Sandra R. Manning,**

*Director, Procurement and Grants Office,  
Centers for Disease Control and Prevention.*  
[FR Doc. 03-13656 Filed 5-30-03; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Active Surveillance for Pertussis—Surveillance for Vaccine Preventable Disease as a Foundation for Evaluating the Effectiveness and Impact of an Adolescent/Adult Pertussis Immunization Program and for Evaluating the Feasibility of a Pediatric Hospital-Based Sentinel Surveillance Network for Vaccine Preventable Diseases, Program Announcement #03101 and Solicitation 2003-N-0837

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease